Vemurafenib Monotherapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Vemurafenib Monotherapy, 2025, version number 6, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6723/102_v6_Vemurafenib_Monotherapy.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. 2

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
HSE (1) BRAF p.V600E Melanoma Vemurafenib
HSE (1) BRAF p.V600K Melanoma Vemurafenib